Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index; 48 of the 126 sources its claims cite were checked for support.
Abstract
Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
Overview
CoChat Summary
TL;DR
An international ATTD consensus panel recommends standardized continuous glucose monitoring (CGM) time-in-range targets to complement A1C for type 1/type 2 diabetes, older/high-risk individuals, and pregnancy. It defines target TIR, TBR, and TAR cutpoints and cites evidence linking TIR to A1C and diabetes complications.
Key findings
- For type 1/type 2 diabetes, the panel recommends TIR 70–180 mg/dL >70% (>16 h 48 min), TBR <70 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), TAR >180 mg/dL <25% (<6 h), and TAR >250 mg/dL <5% (<1 h 12 min). For older/high-risk individuals, TIR target is >50% (>12 h), TBR <70 mg/dL <1% (<15 min), and TAR >250 mg/dL <10% (<2 h 24 min).
- For pregnancy in type 1 diabetes, the target range is 63–140 mg/dL (3.5–7.8 mmol/L), with TIR >70% (>16 h 48 min), TBR <63 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), and TAR >140 mg/dL <25% (<6 h); pregnancy type 2/GDM targets were not included because of limited evidence.
- TIR relates to A1C: TIR 70% and 50% corresponded with A1C approximately 7% (53 mmol/mol) and 8% (64 mmol/mol), respectively; every 10% increase in TIR corresponded to about 0.5% (5.5 mmol/mol) A1C reduction in Beck et al. (n=545 type 1 diabetes) and about 0.8% (8.7 mmol/mol) in Vigersky et al. (n=1,137 type 1/type 2).
- In DCCT data, hazard for retinopathy progression increased by 64% for each 10% reduction in TIR, and microalbuminuria development increased by 40%; in 3,262 people with type 2 diabetes, more advanced diabetic retinopathy was associated with less time in target range. The panel also recommends 14 days of CGM data, >70% CGM active, and %CV target <36% (some studies suggest <33%).
Methods
- Consensus process: in February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes expert in CGM; subgroups reviewed literature and presented evidence-based recommendations to the full panel for voting.
- Data/sample: no new primary trial was conducted; the paper synthesizes cited studies, including Beck et al. (n=545 type 1 diabetes), Vigersky et al. (n=1,137 type 1/type 2), Lu et al. (3,262 type 2 diabetes), DCCT analyses, and pregnancy CGM studies.
- Main analysis: narrative evidence synthesis and expert consensus on CGM metrics, time-in-range cutpoints, and standardized Ambulatory Glucose Profile reporting; no formal meta-analysis or systematic review is described.
Limitations
- The paper states that long-term trials demonstrating how CGM metrics relate to and/or predict clinical outcomes have not been conducted, and the evidence is suggestive; pregnancy percentages are based on limited evidence and more research is needed.
- The paper states there is no evidence regarding time in range for older and/or high-risk individuals, and CGM targets for women with GDM or type 2 diabetes in pregnancy were not included because of lack of evidence.
- Evident from the text: recommendations are consensus/expert opinion rather than a systematic review, and the consensus meeting/manuscript was funded by ATTD with support from multiple industry sponsors; many panel members report industry consulting, speaking, research, or advisory relationships.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 14 Not valid · 24 Not checked · 13 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] 41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358. sourceExperimental — accuracy not yet measured
In type 1 diabetes, the Results (Table 2; page unavailable) show weaker correlations for hypoglycemia and glycemic variability than for mean glucose at 15 days. But they also show that both correlations increase as sampling extends from 3 to 15 days, contrary to the citing sentence’s claim that an increase with longer sampling has not been shown. The paper does not frame this analysis as >70% CGM use over 14 days. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] 41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358. sourceExperimental — accuracy not yet measured
The Results (Table 2; page unavailable) show that correlations with the full three-month data increased as sampling lengthened for both hypoglycemia and glycemic variability. From 3 to 15 days, r² rose from 0.32 to 0.66 for values ≤70 mg/dL and from 0.36 to 0.70 for coefficient of variation—the opposite of the attributed claim. (LLM, conf=0.93)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The first longitudinal CGM data demonstrated a 13percentage point increase in TIR (43% to 56% TIR 70-140 mg/dL [3.9-7.8 mmol/L]) (61).”
What the sources say
- Disputedcites [61] 62. Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. N Engl J Med. 2016;375(7):644-654. sourceExperimental — accuracy not yet measured
The Study Outcomes report different CGM time-in-range results: 59.5% to 74.7% overnight and 56.8% to 66.3% over 24 hours with closed-loop therapy. The paper defines its target range as 63–140 mg/dL, not 70–140 mg/dL; it does not report the claimed increase from 43% to 56%. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Numerous studies have demonstrated significant clinical benefits of CGM use in people with diabetes regardless of insulin delivery method (1-15).”
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317(4):379-387 source
- Partly supportedcites [2] 2. Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care 2017;40(4):538-545. sourceExperimental — accuracy not yet measured
The Introduction reports that several randomized trials found CGM benefits, including reduced HbA1c and hypoglycemia, particularly in adults with type 1 diabetes. But the Conclusions say this trial included only insulin-pump users; extending its results to people using injections is described as reasonable, not demonstrated. The paper therefore does not establish benefits regardless of insulin delivery method or across all people with diabetes. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [3] 3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317:371-378. source
- Not checked — no full text of the sourcecites [4] 4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374. source
- Not checked — no full text of the sourcecites [5] 5. Polonsky WH, Hessler D, Ruedy KJ, Beck RW, for the DIAMOND Study Group. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care 2017; 40:736-741. source
- Supportedcites [6] 6. ϲ͘ ŠŽƵƉĂů J͕ PĞƚƌƵǎĞůŬŽǀĄ L͕ FůĞŬĂē M͕ Ğƚ Ăů͘ CŽŵƉĂƌŝƐŽŶ ŽĨ ĚŝĨĨĞƌĞŶƚ ƚƌĞĂƚŵĞŶƚ ŵŽĚĂůŝƚŝĞƐ ĨŽƌ type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538. source
The Discussion reports significant glycemic benefits from real-time CGM that were comparable with pump (CSII) and injection (MDI) therapy. The study concerns people with type 1 diabetes. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [7] 7. van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, openlabel, crossover trial. Lancet Diabetes Endocrinol. 2016;4(11):893-902. source
- Not checked — no full text of the sourcecites [8] 8. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388:2254-2263. source
- Partly supportedcites [9] 9. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulintreated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55-73. sourceExperimental — accuracy not yet measured
The Results report significant reductions in hypoglycemic events with flash glucose monitoring in adults with insulin-treated type 2 diabetes, supporting a clinical benefit. The Results also state that 95% of participants used an insulin pen or syringe and 5% used continuous subcutaneous insulin infusion; the paper does not establish that the benefit held regardless of insulin delivery method. No page numbers are available in our copy. (LLM, conf=0.85)
- Partly supportedcites [10] 10. Choudhary P, Olsen BS, Conget I, et al. Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Diabetes Technol Ther 2016;18(5):288-291. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says the CGM-based MiniMed 640G pump system can help patients with type 1 diabetes avoid hypoglycemia. But this short, uncontrolled study examined a predictive pump-suspension system, not CGM use regardless of insulin delivery method; it does not establish a benefit across delivery methods or isolate the benefit of CGM itself. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A1C is currently recognized as the key surrogate marker for the development of longterm diabetes complications in people with type 1 and type 2 diabetes and has been used the primary endpoint for many CGM studies (1; 3; 4; 6; 32; 33).”
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317(4):379-387 source
- Not checked — no full text of the sourcecites [3] 3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317:371-378. source
- Not checked — no full text of the sourcecites [4] 4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374. source
- Could not verifycites [6] 6. ϲ͘ ŠŽƵƉĂů J͕ PĞƚƌƵǎĞůŬŽǀĄ L͕ FůĞŬĂē M͕ Ğƚ Ăů͘ CŽŵƉĂƌŝƐŽŶ ŽĨ ĚŝĨĨĞƌĞŶƚ ƚƌĞĂƚŵĞŶƚ ŵŽĚĂůŝƚŝĞƐ ĨŽƌ type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538. sourceExperimental — accuracy not yet measured
The Prespecified outcomes section (page unavailable) identifies HbA1c as this type 1 diabetes study’s primary endpoint. Neither that section nor the Discussion passages establish that A1C is the key surrogate marker for long-term complications in people with both type 1 and type 2 diabetes. Searches for that surrogate-marker relationship and for complications found no passage stating it. (LLM, conf=0.72)
- Partly supportedcites [33] 32. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012;55(12):3155-3162. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) links near-normal glycaemia with reduced complication risk in type 1 diabetes, and Methods > Outcome measure (page unavailable) uses HbA1c as this trial’s primary endpoint. The paper does not establish HbA1c as the key surrogate marker for long-term complications in both type 1 and type 2 diabetes. (LLM, conf=0.81)
- Could not verifycites [32] 31. Novodvorsky P, Bernjak A, Chow E, et al. Diurnal differences in risk of cardiac arrhythmias during spontaneous hypoglycemia in young people with type 1 diabetes. Diabetes Care 2017;40:655 ʹ 662. sourceExperimental — accuracy not yet measured
The Baseline Assessment section says HbA1c was measured at the start of monitoring, but does not describe it as a surrogate marker for long-term complications. The Research Design and Methods section examines arrhythmias during hypoglycemia, not A1C as a primary endpoint in CGM studies. Searches for the surrogate-marker and primary-endpoint claims found no supporting passage in our copy. (LLM, conf=0.76)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
37 more claims · 16 with their cited sources checked
Create a free account to see all 67 claims and to verify the 4 references still open.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the advent of newer studies of CGM in noninsulin‐treated individuals and increasing uptake, the utility of CGM is progressively being endorsed in this population.”
From Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoglycaemia is associated with an increased risk of vascular events, explaining recent consensus advocating hypoglycaemic exposure at <1% (i.e.<15 min/day) in individuals at high CV risk.137,138”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [138]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Considering the older age of participants and comorbid conditions reported, the mean HbA1c, GMI, TIR, and TBR results (8.0%, 7.6%, 56%, and 1.0% at 6 months, respectively) demonstrate close adherence to established glycemic targets (23, 24, 38).”
From Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Avaiable data suggest that such systems can increase TIR and reduce hypoglycemia in patients with DGP, with improvements comparable to those observed in individuals without gastrointestinal complications, although data remain limited and largely observational [153–157].”
From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A subsequent international consensus defined targets for most of the measures on the AGP that would correspond to individualized HbA 1c targets (193).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [193]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ FIGURES / TABLES · p. 4
“2 Figures / 3 Tables”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Time in Ranges · p. 11
“Table 4. Consensus guidance on cutpoints for assessment of glycemic control: Pregnancy”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationState of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citationIsmail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Self-citationBeck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 1×
“A1C is currently recognized as the key surrogate marker for the development of long-termdiabetes complications in people with type 1 and type 2 diabetes and has been used as the primary end point for many CGM studies (1,3,4,6,33,34).”
BackgroundSelf-citationBolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Cited by
Items 101–200 of 3,959
Is HbA1c an ideal biomarker of well-controlled diabetes?
Kaiafa, G. D., Veneti, S., Polychronopoulos, G., Pilalas, D., Daios, S., Kanellos, I., Didangelos, T., Pagoni, S., & Savopoulos, C. G. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138756 · Cited by 184
Shokrekhodaei, M., Cistola, D. P., Roberts, R. C., & Quiñones, S. (2021) · IEEE Access · doi:10.1109/access.2021.3079182 · Cited by 146
“The matrix Z [2] is then plugged into the rectifier linear unit ReLU, an activation function for the output layer, which results in ˆ y (see Fig.”
BackgroundMethodInfluentialBoughton, C. K., Hartnell, S., Thabit, H., Mubita, W. M., Draxlbauer, K., Poettler, T., Wilinska, M. E., Hood, K. K., Mader, J. K., Narendran, P., et al. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00005-8 · Cited by 127
Self-citationTime in range: a new parameter to evaluate blood glucose control in patients with diabetes
Gabbay, M. A. L., Rodacki, M., Calliari, L. E., Vianna, A. G. D., Krakauer, M., Pinto, M. S., Reis, J. S., Puñales, M., Miranda, L. G., Ramalho, A. C., et al. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00529-z · Cited by 126
Capaldo, B., Annuzzi, G., Creanza, A., Giglio, C., Angelis, R. D., Lupoli, R., Masulli, M., Riccardi, G., Rivellese, A. A., & Bozzetto, L. (2020) · Diabetes Care · doi:10.2337/dc20-1127 · Cited by 138
“0 mmol/L) expressed aspercentageof all CGMreadings, mean glucose, and glycemic variability (coefficient of variation [CV%]) were analyzed (2).”
MethodBoughton, C. K., Tripyla, A., Hartnell, S., Daly, A., Herzig, D., Wilinska, M. E., Czerlau, C., Fry, A., Bally, L., & Hovorka, R. (2021) · Nature Medicine · doi:10.1038/s41591-021-01453-z · Cited by 125
Self-citationUsing Continuous Glucose Monitoring in Clinical Practice
Miller, E. M. (2020) · Clinical Diabetes · doi:10.2337/cd20-0043 · Cited by 122
“Briefly, themost useful data elements for clinical decisionmaking are summarized in Table 5 (31).”
BackgroundAbraham, M. B., de Bock, M., Smith, G. J., Dart, J., Fairchild, J. M., King, B. R., Ambler, G. R., Cameron, F. J., McAuley, S. A., Keech, A. C., et al. (2021) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2021.3965 · Cited by 121
A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems
Peacock, S., Frizelle, I., & Hussain, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01394-5 · Cited by 122
BAJAJ, H. S., Bergenstal, R. M., Christoffersen, A., Davies, M. J., Gowda, A., Isendahl, J., Lingvay, I., Senior, P. A., Silver, R., Trevisan, R., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2877 · Cited by 132
Self-citationSherr, J. L., Heinemann, L., Fleming, G. A., Bergenstal, R. M., Bruttomesso, D., Hanaire, H., Holl, R. W., Petrie, J. R., Peters, A. L., & Evans, M. (2023) · Diabetologia · doi:10.1007/s00125-022-05744-z · Cited by 123
“Finally, pregnancy poses a unique situation, as the targets for glycaemia are inherently much more ambitious [12, 62].”
BackgroundSelf-citationEncapsulated stem cell–derived β cells exert glucose control in patients with type 1 diabetes
Keymeulen, B., Groot, K. D., Jacobs‐Tulleneers‐Thevissen, D., Thompson, D. M., Bellin, M. D., KROON, E. J., Daniels, M., Wang, R. M., JAIMAN, M. S., Kieffer, T. J., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-02055-5 · Cited by 165
“The four patients with induced β cell function, as expressed by the primary efficacy endpoint, were evaluated for their glucose control markers over the 12-month period using recommended glucose monitoring measures obtained during CGM 23,24 (Supplementary Table 2).”
Aronson, R., Brown, R. E., Chu, L., Bajaj, H. S., Khandwala, H., Abitbol, A., Malakieh, N., & Goldenberg, R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14949 · Cited by 118
“The greater gain in mean TIR seen in this study is important given that a 5% increase in TIR is considered a clinically meaningful improvement.(22) Further, it occurred without an increase in mean therapies per person.”
BackgroundBraune, K., Lal, R. A., Petruželková, L., Scheiner, G., Winterdijk, P., Schmidt, S., Raimond, L., Hood, K. K., Riddell, M. C., Skinner, T. C., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00267-9 · Cited by 130
McAuley, S. A., Trawley, S., Vogrin, S., Ward, G. M., Fourlanos, S., Grills, C. A., Lee, M. H., Alipoor, A. M., O’Neal, D. N., O’Regan, N. A., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1667 · Cited by 117
Shamanna, P., Saboo, B., Damodharan, S., Mohammed, J., Mohamed, M., Poon, T., Kleinman, N., & Thajudeen, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00931-w · Cited by 115
Self-citationContinuous glucose monitoring for the routine care of type 2 diabetes mellitus
Ajjan, R. A., Battelino, T., Cos, X., Del Prato, S., Philips, J.-C., Meyer, L., Seufert, J., & Seidu, S. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00973-1 · Cited by 117
“…the risk of hypo-glycaemia in T2DM and achieve a time below range in hypoglycaemia of 3.0 mmol/l (54 mg/dl) target of 1% of readings each day 40 , it is important that glycaemic variability, as measured by coefficient of variation over the observation period, remains 30% of the mean…”
InfluentialSelf-citationHigh residual C-peptide likely contributes to glycemic control in type 1 diabetes
Rickels, M. R., Evans-Molina, C., Bahnson, H. T., Ylescupidez, A., Nadeau, K. J., Hao, W., Clements, M. A., Sherr, J. L., Pratley, R. E., Hannon, T. S., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134057 · Cited by 113
Predieri, B., Leo, F., Candia, F., Lucaccioni, L., Madeo, S. F., Pugliese, M., Vivaccia, V., Bruzzi, P., & Iughetti, L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.595735 · Cited by 110
Malahi, A. E., Elsen, M. V., Charleer, S., Dirinck, E. L., Ledeganck, K. J., Keymeulen, B., Crenier, L., Radermecker, R. P., Taes, Y., Vercammen, C., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab688 · Cited by 131
“With the use of CGM, an International Consensus on Time in Range was recently published with the recommendation to spend >70% of time in range (70-180 mg/dL or 3.9-10 mmol/L) because this level corresponds to an HbA1c level of 7.0% (53 mmol/mol) (12, 13).”
InfluentialSelf-citationPeralta, F. G., Choudhary, P., Cosson, E., Irace, C., Rami-Merhar, B. M., & Seibold, A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14638 · Cited by 121
Beck, R. W., Kanapka, L. G., Breton, M. D., Brown, S. A., Wadwa, R. P., Buckingham, B. A., Kollman, C., & Kovatchev, B. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0558 · Cited by 111
Self-citationJacobs, P. G., Herrero, P., Facchinetti, A., Vehi, J., Kovatchev, B., Breton, M. D., Cinar, A., Nikita, K. S., Doyle, F. J., Bondia, J., et al. (2024) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2023.3331297 · Cited by 113
Self-citationGerhardsson, P., Schwandt, A., Witsch, M., Kordonouri, O., Svensson, J., Forsander, G., Battelino, T., Veeze, H., Danne, T., & on Behalf of the SWEET Study Group (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0618 · Cited by 106
“3 SWEET will perhaps decide for open/public benchmarking, and together with ISPAD adopts and further develops new technology-based diabetes management strate-giesandtargets 31 forallparticipatingcenters tofosteradditional improvements in glycemic control.”
Self-citationArtificial intelligence biosensors for continuous glucose monitoring
Jin, X., Cai, A., Xu, T., & Zhang, X. (2023) · Interdisciplinary materials · doi:10.1002/idm2.12069 · Cited by 164
“[8] Additionally, the CGM biosensor is vital to enable a closed ‐ loop that relies on real ‐ time glucose data.”
BackgroundInterpreting blood GLUcose data with R package iglu
Broll, S., Urbanek, J., Buchanan, D., Chun, E., Muschelli, J., Punjabi, N. M., & Gaynanova, I. (2021) · PLOS ONE · doi:10.1371/journal.pone.0248560 · Cited by 107
“Fig 1 illustrates the default output on example data with the horizontal red lines indicating user-specified target range, the default range is [70, 180] mg/dL [27].”
Petrovski, G., Campbell, J., Pasha, M., Day, E., Hussain, K., Khalifa, A., & van den Heuvel, T. (2023) · Diabetes Care · doi:10.2337/dc22-1692 · Cited by 108
Dicembrini, I., Cosentino, C., Monami, M., Mannucci, E., & Pala, L. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01589-3 · Cited by 106
“The wider use of CGM devices prompted also the introduction of new potential parameters for the assessment of glucose control, such as glycemic variability (often expressed as coefficient of variation or mean amplitude of glucose excursions), and time in range [9].”
BackgroundCastañeda, J., Arrieta, A., van den Heuvel, T., Battelino, T., & Cohen, O. (2024) · Diabetes Care · doi:10.2337/dc23-1581 · Cited by 107
Self-citationPredictors of time in target glucose range in real‐world users of the MiniMed 780G system
Castañeda, J., Mathieu, C., Aanstoot, H., Arrieta, A., Da Silva, J., Shin, J., & Cohen, O. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14807 · Cited by 106
“0%, well below the recommended threshold of 4%.(8) When the target was set at 100 mg/dl (5.”
BackgroundSelf-citationType 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring
Jackson, M. A., Ahmann, A., & Shah, V. N. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0007 · Cited by 106
“Keywords: Type 2 diabetes, Continuous glucose monitor, Glucose monitoring, Glycemic control, HbA1c.”
BackgroundMethodInfluentialRaj, R., Mishra, R., Jha, N., Joshi, V. R., Correa, R. R., & Kern, P. A. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002573 · Cited by 125
Elbalshy, M., Haszard, J., Smith, H., Kuroko, S., Galland, B., Oliver, N., Shah, V., de Bock, M. I., & Wheeler, B. J. (2022) · Diabetic Medicine · doi:10.1111/dme.14854 · Cited by 104
Whole-Grain Processing and Glycemic Control in Type 2 Diabetes: A Randomized Crossover Trial
Åberg, S., Mann, J., Neumann, S., Ross, A. B., & Reynolds, A. N. (2020) · Diabetes Care · doi:10.2337/dc20-0263 · Cited by 102
The competitive athlete with type 1 diabetes
Riddell, M. C., Scott, S. N., Fournier, P. A., Colberg, S. R., Gallen, I. W., Moser, O., Stettler, C., Yardley, J. E., Zaharieva, D. P., Adolfsson, P., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05183-8 · Cited by 101
Holzer, R., Bloch, W., & Brinkmann, C. K. (2022) · Sensors · doi:10.3390/s22052030 · Cited by 130
“The American Diabetes Association (ADA) recommends a TIR of >70% for people with diabetes [28].”
BackgroundHypoglycemia in patient with type 2 diabetes treated with insulin: it can happen
Heller, S. R., Peyrot, M., Oates, S. K., & Taylor, A. D. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001194 · Cited by 101
Self-citationISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring
Tauschmann, M., Forlenza, G., Hood, K., Cardona‐Hernandez, R., Giani, E., Hendrieckx, C., DeSalvo, D. J., Laffel, L. M., Saboo, B., Wheeler, B. J., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13451 · Cited by 100
Self-citationZeng, B., Gao, L., Yang, Q., Jia, H., & Sun, F. (2023) · Diabetes Care · doi:10.2337/dc23-0504 · Cited by 100
Yoo, J. H., Choi, M. S., Ahn, J., Park, S. W., Kim, Y., Hur, K. Y., Jin, S.-M., Kim, G., & Kim, J. H. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0499 · Cited by 98
“15 As the use of CGM is rapidly growing as an essential part of diabetes management in clinical practice, the need to investigate whether TIR and other CGM parameters are related to diabetes complications as HbA1c is increasing.”
Abraham, M. B., Karges, B., Dovč, K., Naranjo, D. M., Arbeláez, A. M., Mbogo, J., Javelikar, G., Jones, T. W., & Mahmud, F. H. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13443 · Cited by 141
“These definitions have informed the standardization of CGM metrics to set clinical targets for CGM data interpretation.(13)”
BackgroundSelf-citationDovc, K., Piona, C., Yeşiltepe Mutlu, G., Bratina, N., Jenko Bizjan, B., Lepej, D., Nimri, R., Atlas, E., Muller, I., Kordonouri, O., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0895 · Cited by 96
Self-citationSherr, J. L., Bode, B. W., Forlenza, G. P., Laffel, L. M., Schoelwer, M. J., Buckingham, B. A., Criego, A. B., DeSalvo, D. J., MacLeish, S. A., Hansen, D. W., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2359 · Cited by 97
“5-fold, while more than four in five achieved the less stringent >60% TIR goal (14).”
BackgroundSelf-citationStrategies to Enhance New CGM Use in Early Childhood (SENCE) Study Group, Laffel, L., Harrington, K., Hanono, A., Naik, N., Ambler-Osborn, L., Schultz, A., DiMeglio, L., Woerne, S., Jolivette, H., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1060 · Cited by 95
Self-citationLingvay, I., Buse, J. B., Franek, E., Hansen, M. V., Koefoed, M. M., Mathieu, C., Pettus, J., Stachlewska, K., & Rosenstock, J. (2021) · Diabetes Care · doi:10.2337/dc20-2878 · Cited by 110
Self-citationCGMap: Characterizing continuous glucose monitor data in thousands of non-diabetic individuals
Keshet, A., Shilo, S., Godneva, A., Talmor‐Barkan, Y., Aviv, Y., Segal, E., & Rossman, H. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.04.002 · Cited by 111
Use of Continuous Glucose Monitors by People Without Diabetes: An Idea Whose Time Has Come?
Klonoff, D. C., Nguyen, K. T., Xu, N. Y., Gutierrez, A., Espinoza, J. C., & Vidmar, A. P. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221110830 · Cited by 93
Sherr, J. L., Buckingham, B. A., Forlenza, G. P., Galderisi, A., Ekhlaspour, L., Wadwa, R. P., Carria, L., Hsu, L., Berget, C., Peyser, T. A., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0286 · Cited by 92
“13,21,28 The results achieved for time with sensor glucose in and below the target range are also consistent with recommended clinical targets for these glycemic measures for adults and youth, which were informed by the results achieved by HCL systems to date.”
InfluentialSelf-citationForlenza, G. P., DeSalvo, D. J., Aleppo, G., Wilmot, E. G., Berget, C., Huyett, L. M., Hadjiyianni, I., Méndez, J. J., Conroy, L. R., Ly, T. T., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0578 · Cited by 99
“…sample also came close to or met consensus guidelines for TIR and time below range in both groups when using an average glucose target of 110 mg/dL. 40 These results are consistent with glycemic outcomes reported in a separate study of a similar size under real-world conditions for Medicare ( n =…”
HbA1c and Glucose Management Indicator Discordance: A Real-World Analysis
Perlman, J. E., Gooley, T. A., McNulty, B., Meyers, J., & Hirsch, I. B. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0501 · Cited by 93
“That said, CGM has become a standard of care in many settings, so it is critical that we find ways to integrate these metrics (including time in range [TIR], time above range [TAR], and GMI) into both clinical care and research.(15) A recent publication demonstrated linear relationships between TIR and TAR and mean gl…”
BackgroundSelf-citationGenetic manipulation of anti-nutritional factors in major crops for a sustainable diet in future
Duraiswamy, A., Nancy Mano Sneha, A., Sherina Jebakani, K., Selvaraj, S., Pramitha, L., Ramchander, S., Petchiammal, K. I., Sharmili, K. S., Thinakaran, J., Samundeswari, R., et al. (2023) · Frontiers in Plant Science · doi:10.3389/fpls.2022.1070398 · Cited by 100
Speight, J., Choudhary, P., Wilmot, E. G., Hendrieckx, C., Forde, H., Cheung, W. Y., Crabtree, T., Millar, B., Traviss‐Turner, G., Hill, A., et al. (2023) · Diabetic Medicine · doi:10.1111/dme.14944 · Cited by 92
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T., Karges, B., Kordonouri, O., et al. (2016) · Diabetologie und Stoffwechsel · doi:10.1055/s-0042-111213 · Cited by 91
Self-citationBiester, T., Berget, C., Boughton, C. K., Cudizio, L., Ekhlaspour, L., Hilliard, M. E., Reddy, L., Sap, S. N. U., Schoelwer, M. J., Sherr, J. L., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543034 · Cited by 129
Self-citationMoser, O., Riddell, M. C., Eckstein, M. L., Adolfsson, P., Rabasa‐Lhoret, R., Boom, L., Gillard, P., Nørgaard, K., Oliver, N. S., Zaharieva, D. P., et al. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13105 · Cited by 91
Self-citationTime in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control
Yoo, J. H., & Kim, J. H. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0257 · Cited by 107
Hermanns, N., Ehrmann, D., Shapira, A., Kulzer, B., Schmitt, A., & Laffel, L. (2022) · Diabetologia · doi:10.1007/s00125-022-05685-7 · Cited by 89
Self-citationThomsen, M. N., Skytte, M. J., Samkani, A., Carl, M. H., Weber, P., Astrup, A., Chabanova, E., Fenger, M., Frystyk, J., Hartmann, B., et al. (2022) · Diabetologia · doi:10.1007/s00125-021-05628-8 · Cited by 90
“9–10 mmol/l) as well as time above/below range [19].”
BackgroundSCOTT, E. M., Murphy, H. R., Kristensen, K. H., Feig, D. S., Kjölhede, K., Englund‐Ögge, L., Berntorp, K. E., & Law, G. R. (2022) · Diabetes Care · doi:10.2337/dc22-0078 · Cited by 104
Self-citationNew advances in type 1 diabetes
Subramanian, S., Khan, F., & Hirsch, I. B. (2024) · BMJ · doi:10.1136/bmj-2023-075681 · Cited by 88
“52 Figure 3 shows an ambulatory glucose profile.”
BackgroundSelf-citationBeato-Víbora, P. I., Gallego-Gamero, F., Ambrojo-López, A., Gil-Poch, E., Martín-Romo, I., & Arroyo-Díez, F. J. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0037 · Cited by 87
“20,21 The percentage of individuals who achieved both recommendations, a TIR 70–180 mg/dL > 70% and a time 70 mg/dL 4%, increased from 31% at baseline to 60% at the 1-month evaluation.”
Crabtree, T. S. J., Griffin, T. P., Yap, Y. W., Narendran, P., Gallen, G., Furlong, N., Cranston, I., Chakera, A., Philbey, C., Karamat, M. A., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0635 · Cited by 88
“over 14 days per the international consensus guidelines and in keeping with routine clinical practice (20).”
Bergenstal, R. M., Mullen, D. M., Strock, E., Johnson, M. L., & Xi, M. X. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108106 · Cited by 87
Self-citationDi Dalmazi, G., Maltoni, G., Bongiorno, C., Tucci, L., Di Natale, V., Moscatiello, S., Laffi, G., Pession, A., Zucchini, S., & Pagotto, U. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001664 · Cited by 87
Non-invasive Monitoring of Three Glucose Ranges Based On ECG By Using DBSCAN-CNN
Li, J., Igbe, T., Liu, Y., Kandwal, A., Wang, L., & Nie, Z. (2021) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2021.3072628 · Cited by 93
McVean, J., Forlenza, G. P., Beck, R. W., Bauza, C., Bailey, R., Buckingham, B., DiMeglio, L. A., Sherr, J. L., Clements, M., Neyman, A., et al. (2023) · JAMA · doi:10.1001/jama.2023.2063 · Cited by 85
Self-citationScott, E. M., Feig, D. S., Murphy, H. R., Law, G. R., The CONCEPTT Collaborative Group, Murphy, H., Grisoni, J., Byrne, C., Neoh, S., Davenport, K., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2527 · Cited by 85
“Although standard summary metrics are recommended for the reporting of CGM (5,6), they do not give dynamic information about the timing of glucose excursions, thereby losing much of the detailed temporal glycemic information generated.”
BackgroundSelf-citationLin, Y. K., Fisher, S. J., & Pop‐Busui, R. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13290 · Cited by 82
Blauw, H., Onvlee, A. J., Klaassen, M., van Bon, A. C., & DeVries, J. H. (2021) · Diabetes Care · doi:10.2337/dc20-2106 · Cited by 84
Self-citationCastellana, M., Parisi, C., Di Molfetta, S., Di Gioia, L., Natalicchio, A., Perrini, S., Cignarelli, A., Laviola, L., & Giorgino, F. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001092 · Cited by 84
Evolution of Diabetes Technology
Dovč, K., & Battelino, T. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.009 · Cited by 132
Self-citationGarg, S. K., Liljenquist, D., Bode, B., Christiansen, M. P., Bailey, T. S., Brazg, R. L., Denham, D. S., Chang, A. R., Akturk, H. K., Dehennis, A., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0182 · Cited by 83
“In addition, analysis of real-time CGM data allows patients and their health care providers to analyze patterns and trends to alter aspects of the diabetes regimen, as well as determine if established targets for glucose levels, such as time in range and percentage of time spent above and time spent below range, are b…”
Self-citationBeck, R. W., Raghinaru, D., Calhoun, P. M., & Bergenstal, R. M. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0380 · Cited by 86
Self-citationPrahalad, P., Ding, V. Y., Zaharieva, D. P., Addala, A., Johari, R., Scheinker, D., Desai, M., Hood, K., & Maahs, D. M. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab859 · Cited by 82
Closed-loop control in insulin pumps for type-1 diabetes mellitus: safety and efficacy
Fuchs, J., & Hovorka, R. (2020) · Expert Review of Medical Devices · doi:10.1080/17434440.2020.1784724 · Cited by 82
“Based on consensus statements on the reporting of CGM data, the most common outcome measures of glycaemic control are (27, 34): mean sensor glucose; time in the normoglycaemic range defined as between 3.”
BackgroundSelf-citationChinese diabetes datasets for data-driven machine learning
Zhao, Q., Zhu, J., Shen, X., Lin, C., Zhang, Y., Liang, Y., Cao, B., Li, J., Liu, X., Rao, W., et al. (2023) · Scientific Data · doi:10.1038/s41597-023-01940-7 · Cited by 129
“6), we found that the standard deviations of TBR, TIR and TAR in the ShanghaiT1DM were higher than those in the OhioT1DM .”
MethodInfluentialGilbert, T. R., Noar, A., Blalock, O., & Polonsky, W. H. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0666 · Cited by 81
Beardsall, K., Thomson, L., Guy, C., Iglesias-Platas, I., van Weissenbruch, M. M., Bond, S., Allison, A., Kim, S., Petrou, S., Pantaleo, B., et al. (2021) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(20)30367-9 · Cited by 82
Self-citationThe Artificial Pancreas and Type 1 Diabetes
Nwokolo, M., & Hovorka, R. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad068 · Cited by 119
“Hybrid closed-loop systems have set a new benchmark for optimal time in range, an international consensus recommended glucose metric (53) shown to correlate with diabetes complications and HbA1c (54, 55); however, significant challenges with heterogeneous data, clinical implementation, and…”
BackgroundSelf-citationAkturk, H. K., Giordano, D., Champakanath, A., Brackett, S., Garg, S., & Snell‐Bergeon, J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13933 · Cited by 80
“Time spent in hyperglycaemia (>180 and >250 mg/dL) should be <25% and <5%, respectively.(19) In our study, patients reached recommended TIR targets (70.”
BackgroundSelf-citationThe trials and tribulations of determining HbA1c targets for diabetes mellitus
Klein, K. R., & Buse, J. B. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00425-6 · Cited by 97
Choudhary, P., Arrieta, A., van den Heuvel, T. R. A., Castañeda, J., Smaniotto, V., & Cohen, O. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0433 · Cited by 89
“14 The minimal bias in our data becomes evident through the consistent results as shown in this and previous reports, on data across various population sizes, 12,15 age groups, 12 and geographic locations.”
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., Brown, F. M., ChallaSivaKanaka, S., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s015 · Cited by 176
Self-citationPerformance of the Dexcom G6 Continuous Glucose Monitoring System in Pregnant Women with Diabetes
Castorino, K., Polsky, S., O'Malley, G., Levister, C., Nelson, K., Farfan, C., Brackett, S., Puhr, S., & Levy, C. J. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0085 · Cited by 79
Forlenza, G. P., Buckingham, B. A., Brown, S. A., Bode, B. W., Levy, C. J., Criego, A. B., Wadwa, R. P., Cobry, E. C., Slover, R. J., Messer, L. H., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0546 · Cited by 78
Self-citationTechnological Advances of Wearable Device for Continuous Monitoring of In Vivo Glucose
Huang, X., Yao, C., Huang, S., Zheng, S., Liu, Z., Liu, J., Wang, J., Chen, H., & Xie, X. (2024) · ACS Sensors · doi:10.1021/acssensors.3c01947 · Cited by 90
ADIPS 2020 guideline for pre‐existing diabetes and pregnancy
Rudland, V. L., Price, S., Hughes, R. C. E., Barrett, H. L., Lagstrom, J., Porter, C., Britten, F. L., Glastras, S. J., Fulcher, I., Wein, P., et al. (2020) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13265 · Cited by 87
Bisio, A., Gonder-Frederick, L., McFadden, R., Cherñavvsky, D., Voelmle, M., Pajewski, M., Yu, P., Bonner, H., & Brown, S. A. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820986879 · Cited by 76
Dunn, T. C., Ajjan, R., Bergenstal, R. M., & Xu, Y. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0565 · Cited by 97
“TITR was identified and recommended recently as an important additional CGM-derived glucose metric covering glucose ranges of 70– 140 mg/dL 8,9 and which can be considered as an alternative to TIR according to study and participant management goals.”
BackgroundSelf-citationBöhm, A.-K., Jensen, M. L., Sørensen, M. R., & Stargardt, T. (2020) · JMIR mHealth and uHealth · doi:10.2196/22212 · Cited by 76
“In this study, baseline glycemic control was assessed based on recommended target ranges established by an international expert panel in 2019 [26].”
MethodReal-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes
Messer, L. H., Berget, C., Pyle, L., Vigers, T., Cobry, E., Driscoll, K. A., & Forlenza, G. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0165 · Cited by 76
Oral nanotherapeutic formulation of insulin with reduced episodes of hypoglycaemia
Hunt, N. J., Lockwood, G. P., Heffernan, S. J., Daymond, J., Ngu, M., Narayanan, R. K., Westwood, L. J., Mohanty, B., Esser, L., Williams, C. C., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-023-01565-2 · Cited by 83
“…injectable or infusions of insulin, lifestyle interventions and continuous glucose monitoring to reduce the incidence of acute adverse events (hyperglycaemia and hypoglycaemia) and the development of long-term complications such as cardiovascular disease 3 or nephro-, neuro-and retin-opathies 4–7 .”
Jiao, X., Shen, Y., & Chen, Y. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002633 · Cited by 76
“…for glucose levels to fall in the target range according to the recommendations of the guidelines for T1DM, starting from 70 mg/dL to 180 mg/ dL. 22 23 Besides being reflective of the day- to-day experience of individuals with diabetes, 24 TIR can be used to predict the risk of future diabetic…”
Maddaloni, E., Coraggio, L., Pieralice, S., Carlone, A., Pozzilli, P., & Buzzetti, R. (2020) · Diabetes Care · doi:10.2337/dc20-0954 · Cited by 80
“No significant changes in glucosemetricswere found between subgroups by baseline TIR or by insulin regimen (MDI or CSII).”
MethodInfluentialCastellanos, L. E., Balliro, C. A., Sherwood, J. S., Jafri, R., Hillard, M. A., Greaux, E., Selagamsetty, R., Zheng, H., El-Khatib, F. H., Damiano, E. R., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1086 · Cited by 74
A Consensus Statement for Continuous Glucose Monitoring Metrics for Inpatient Clinical Trials
Spanakis, E. K., Cook, C. B., Kulasa, K. M., Aloi, J., Bally, L., Davis, G. M., Dungan, K. M., Galindo, R. J., Mendez, C. E., Pasquel, F. J., et al. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231191104 · Cited by 92
Rodbard, D. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0440 · Cited by 75
Self-citationLing, J., Ng, J. K., Chan, J. C. N., & Chow, E. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.869899 · Cited by 88
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Ranjan, A. G., Rosenlund, S. V., Hansen, T. W., Rossing, P., Andersen, S., & Nørgaard, K. (2020) · Diabetes Care · doi:10.2337/dc20-0909 · Cited by 72
Self-citation
Metadata
- Authors
- Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., Cobelli, C., Dassau, E., DeVries, J. H., Donaghue, K. C., Dovc, K., Doyle, F. J., Garg, S., Grunberger, G., Heller, S., Heinemann, L., Hirsch, I. B., Hovorka, R., Jia, W., Kordonouri, O., Kovatchev, B., Kowalski, A., Laffel, L., Levine, B., Mayorov, A., Mathieu, C., Murphy, H. R., Nimri, R., Nørgaard, K., Parkin, C. G., Renard, E., Rodbard, D., Saboo, B., Schatz, D., Stoner, K., Urakami, T., Weinzimer, S. A., & Phillip, M.
- Affiliations
- University of Ljubljana (SI)
- Kinderkrankenhaus auf der Bult (DE)
- Park Nicollet Health Services (US)
- King's College London (GB)
- Jaeb Center for Health Research (US)
- Vita-Salute San Raffaele University (IT)
- Stanford Medicine (US)
- American Diabetes Association (US)
- Close Concerns (United States) (US)
- University of Padua (IT)
- Harvard University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- The University of Sydney (AU)
- Department of Pediatric Endocrinology, Diabetes and Metabolism, University Children’s Hospital, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Slovenia
- University of Colorado Denver (US)
- Grunberger Diabetes Institute (US)
- University of Sheffield (GB)
- Science Consulting in Diabetes, Neuss, Germany
- University of Washington (US)
- University of Cambridge (GB)
- Shanghai Jiao Tong University (CN)
- University of Virginia (US)
- Breakthrough T1D (US)
- Joslin Diabetes Center (US)
- Endocrinology Research Center (RU)
- KU Leuven (BE)
- University of East Anglia (GB)
- Schneider Children's Medical Center (IL)
- Steno Diabetes Center Copenhagen (DK)
- CGParkin Communications, Inc., Henderson, NV
- Department of Endocrinology, Diabetes, and Nutrition, Montpellier University Hospital; Institute of Functional Genomics, University of Montpellier; and INSERM Clinical Investigation Centre, Montpellier, France
- Biomedical Informatics Consultants LLC, Potomac, MD
- DiaCare, Ahmedabad, Gujarat, India
- University of Florida (US)
- dQ&A Market Research, Inc., San Francisco, CA
- Nihon University (JP)
- Yale University (US)
- Tel Aviv University (IL)
- Corresponding author
- Battelino, Tadej
- ORCID
- Battelino, Tadej
- Danne, Thomas
- Bergenstal, Richard M.
- Amiel, Stephanie A.
- Beck, Roy
- Biester, Torben
- Bosi, Emanuele
- Buckingham, Bruce A.
- Cefalu, William T.
- Close, Kelly L.
- Cobelli, Claudio
- Dassau, Eyal
- DeVries, J. Hans
- Donaghue, Kim C.
- Doyle, Francis J.
- Garg, Satish
- Grunberger, George
- Heller, Simon
- Heinemann, Lutz
- Hirsch, Irl B.
- Hovorka, Roman
- Jia, Weiping
- Kordonouri, Olga
- Kovatchev, Boris
- Kowalski, Aaron
- Laffel, Lori
- Levine, Brian
- Mayorov, Alexander
- Mathieu, Chantal
- Murphy, Helen R.
- Nimri, Revital
- Nørgaard, Kirsten
- Parkin, Christopher G.
- Renard, Eric
- Rodbard, David
- Saboo, Banshi
- Schatz, Desmond
- Stoner, Keaton
- Urakami, Tatsuiko
- Weinzimer, Stuart A.
- Phillip, Moshe
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-08
- Volume
- 42
- Issue
- 8
- Pages
- 1593-1603
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6973648
- OpenAlex
- W2948261890
- Cited by
- 4,237
- References
- 96
- Citations by year
- 2026: 716 · 2025: 649 · 2024: 655 · 2023: 575 · 2022: 619 · 2021: 556 · 2020: 398 · 2019: 61
- FWCI
- 215.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Lirias (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Leona M. and Harry B. Helmsley Charitable Trust
- University of Virginia
- Insulet Corporation
- MannKind Corporation
- Dexcom
- OPKO Health
- Steno Diabetes Center Copenhagen (SDCC 3.E Technology)
- National Institute for Health and Care Research (NF-SI-0515-10079, CDF-2013-06-035, 16/35/01)
- Universiteit van Amsterdam
- KU Leuven
- Novo Nordisk
- Roche Diabetes Care
- National Institutes of Health (UL1TR001863)
- U.S. Food and Drug Administration
- Abbott Diabetes Care
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- continuous glucose monitoring, time in range, glycemic targets, diabetes management, clinical guidelines
- MeSH terms
- Data Accuracy, Blood Glucose, Data Interpretation, Statistical, Diabetes Mellitus, Glycated Hemoglobin, Humans, Patient Care Planning, Reference Values, Time Factors, Blood Glucose Self-Monitoring, Practice Guidelines as Topic, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.